Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Diabetes

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 115 articles:
HTML format



Single Articles


    April 2021
  1. MIZELLE RM JR
    Diabetes, race, and amputations.
    Lancet. 2021;397:1256-1257.
    PubMed    


    March 2021
  2. DEVI S
    Aid agencies turn attention to diabetes.
    Lancet. 2021;397:1049-1050.
    PubMed    


  3. DAVIES M, Faerch L, Jeppesen OK, Pakseresht A, et al
    Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
    Lancet. 2021 Mar 2. pii: S0140-6736(21)00213.
    PubMed     Abstract available


    January 2021
  4. MINGRONE G, Panunzi S, De Gaetano A, Guidone C, et al
    Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial.
    Lancet. 2021;397:293-304.
    PubMed     Abstract available


  5. MIRAS AD, le Roux CW
    Metabolic surgery versus conventional therapy in type 2 diabetes.
    Lancet. 2021;397:256-257.
    PubMed    


  6. BERGENSTAL RM, Nimri R, Beck RW, Criego A, et al
    A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial.
    Lancet. 2021;397:208-219.
    PubMed     Abstract available


    December 2020
  7. THOMPSON KM
    Poliovirus vaccine options: another step forward.
    Lancet. 2020 Dec 9. pii: S0140-6736(20)32629.
    PubMed    


    November 2020
  8. ZACCARDI F, Khunti K, Marx N, Davies MJ, et al
    First-line treatment for type 2 diabetes: is it too early to abandon metformin?
    Lancet. 2020;396:1705-1707.
    PubMed    


  9. THE LANCET
    Turning evidence into action on diabetes.
    Lancet. 2020;396:1535.
    PubMed    


  10. CHAN JCN, Lim LL, Wareham NJ, Shaw JE, et al
    The Lancet Commission on diabetes: using data to transform diabetes care and patient lives.
    Lancet. 2020 Nov 12. pii: S0140-6736(20)32374.
    PubMed    


  11. DAIN K
    Data-driven policies needed to turn the tide on diabetes.
    Lancet. 2020 Nov 12. pii: S0140-6736(20)32378.
    PubMed    


  12. WATTS G
    Rury Holman: the science of diabetes and a life of trials.
    Lancet. 2020 Nov 12. pii: S0140-6736(20)32380.
    PubMed    


    September 2020

  13. NCD Countdown 2030: pathways to achieving Sustainable Development Goal target 3.4.
    Lancet. 2020;396:918-934.
    PubMed     Abstract available


  14. BOXHOORN L, Voermans RP, Bouwense SA, Bruno MJ, et al
    Acute pancreatitis.
    Lancet. 2020;396:726-734.
    PubMed     Abstract available


    August 2020
  15. ZANNAD F, Ferreira JP, Pocock SJ, Anker SD, et al
    SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Lancet. 2020 Aug 28. pii: S0140-6736(20)31824.
    PubMed     Abstract available


    July 2020
  16. BHATT DL, Steg PG
    Differential effect of ticagrelor on irreversible harms in diabetes - Authors' reply.
    Lancet. 2020;396:93-94.
    PubMed    


  17. CHI G, Marszalek J
    Differential effect of ticagrelor on irreversible harms in diabetes.
    Lancet. 2020;396:93.
    PubMed    


  18. REGAN J
    Collaborating on kidneys: Haiti's transplantation ambitions.
    Lancet. 2020;396:15-16.
    PubMed    


    March 2020
  19. ZHOU F, Yu T, Du R, Fan G, et al
    Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
    Lancet. 2020 Mar 11. pii: S0140-6736(20)30566.
    PubMed     Abstract available


    February 2020

  20. Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial.
    Lancet. 2020;395:698-708.
    PubMed     Abstract available


  21. OLIVA-DAMASO N, Oliva-Damaso E, Payan J, Porrini E, et al
    Dulaglutide slows kidney disease in type 2 diabetes.
    Lancet. 2020;395:559.
    PubMed    


  22. GERSTEIN HC
    Dulaglutide slows kidney disease in type 2 diabetes - Author's reply.
    Lancet. 2020;395:559-560.
    PubMed    



  23. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    Lancet. 2020 Feb 13. pii: S0140-6736(20)30045.
    PubMed     Abstract available


    January 2020
  24. HEERSPINK HJL, Parving HH, de Zeeuw D
    Atrasentan in patients with diabetes and chronic kidney disease - Authors' reply.
    Lancet. 2020;395:270.
    PubMed    


  25. SEPE V, Libetta C
    Atrasentan in patients with diabetes and chronic kidney disease.
    Lancet. 2020;395:269.
    PubMed    


  26. LIU D, Liu Z
    Atrasentan in patients with diabetes and chronic kidney disease.
    Lancet. 2020;395:269-270.
    PubMed    


  27. HEIDA JE, Gansevoort RT, van Beek AP
    Use of copeptin in the diagnosis of polyuria-polydipsia syndrome.
    Lancet. 2020;395:267.
    PubMed    


  28. GARRETT C, Ismail K
    Forgotten: mental health interventions in type 1 diabetes.
    Lancet. 2020;395:115.
    PubMed    


    October 2019
  29. BERGENSTAL RM, Johnson ML, Bashan E, Hodish I, et al
    Insulin dosing guidance to optimise type 2 diabetes management - Authors' reply.
    Lancet. 2019;394:1321.
    PubMed    


  30. GARG R
    Insulin dosing guidance to optimise type 2 diabetes management.
    Lancet. 2019;394:1320-1321.
    PubMed    


    September 2019
  31. MOSENZON O, Leibowitz G
    VERIFY the role of initial combination therapy in patients with type 2 diabetes.
    Lancet. 2019 Sep 17. pii: S0140-6736(19)32165.
    PubMed    


  32. MATTHEWS DR, Paldanius PM, Proot P, Chiang Y, et al
    Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.
    Lancet. 2019 Sep 17. pii: S0140-6736(19)32131.
    PubMed     Abstract available


  33. BECK RW, Bergenstal RM, Laffel LM, Pickup JC, et al
    Advances in technology for management of type 1 diabetes.
    Lancet. 2019 Sep 13. pii: S0140-6736(19)31142.
    PubMed     Abstract available


  34. DAYAN CM, Korah M, Tatovic D, Bundy BN, et al
    Changing the landscape for type 1 diabetes: the first step to prevention.
    Lancet. 2019 Sep 13. pii: S0140-6736(19)32127.
    PubMed     Abstract available


  35. VANTYGHEM MC, de Koning EJP, Pattou F, Rickels MR, et al
    Advances in beta-cell replacement therapy for the treatment of type 1 diabetes.
    Lancet. 2019 Sep 13. pii: S0140-6736(19)31334.
    PubMed     Abstract available


    August 2019
  36. VALGIMIGLI M, Manavifar N
    Ticagrelor in patients with diabetes and previous PCI.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31957.
    PubMed    


  37. BHATT DL, Steg PG, Mehta SR, Leiter LA, et al
    Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
    Lancet. 2019 Aug 30. pii: S0140-6736(19)31887.
    PubMed     Abstract available


  38. ROSHANDEL G, Khoshnia M, Poustchi H, Hemming K, et al
    Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
    Lancet. 2019;394:672-683.
    PubMed     Abstract available


  39. ZELNIKER TA, Wiviott SD, Raz I, Sabatine MS, et al
    SGLT-2 inhibitors for people with type 2 diabetes - Authors' reply.
    Lancet. 2019;394:560-561.
    PubMed    


  40. STRANDBERG TE, Petrovic M, Benetos A
    SGLT-2 inhibitors for people with type 2 diabetes.
    Lancet. 2019;394:560.
    PubMed    


  41. MALAGA G, Ruiz EF
    SGLT-2 inhibitors for people with type 2 diabetes.
    Lancet. 2019;394:559-560.
    PubMed    


  42. BARNETT R
    Type 2 diabetes.
    Lancet. 2019;394:557.
    PubMed    


  43. HOORN EJ
    Testing the waters: a new test for hypotonic polyuria.
    Lancet. 2019;394:546-547.
    PubMed    


  44. LEVAILLANT M, Lievre G, Baert G
    Ending diabetes in Mexico.
    Lancet. 2019;394:467-468.
    PubMed    


    July 2019
  45. WINZELER B, Cesana-Nigro N, Refardt J, Vogt DR, et al
    Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study.
    Lancet. 2019 Jul 11. pii: S0140-6736(19)31255.
    PubMed     Abstract available


  46. HOLST JJ
    Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?
    Lancet. 2019;394:4-6.
    PubMed    


    June 2019
  47. GERSTEIN HC, Colhoun HM, Dagenais GR, Diaz R, et al
    Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
    Lancet. 2019 Jun 7. pii: S0140-6736(19)31149.
    PubMed     Abstract available


  48. VERMA S, Mazer CD, Perkovic V
    Is it time to REWIND the cardiorenal clock in diabetes?
    Lancet. 2019 Jun 7. pii: S0140-6736(19)31267.
    PubMed    


  49. GERSTEIN HC, Colhoun HM, Dagenais GR, Diaz R, et al
    Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
    Lancet. 2019 Jun 7. pii: S0140-6736(19)31150.
    PubMed     Abstract available


  50. PRATLEY R, Amod A, Hoff ST, Kadowaki T, et al
    Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Lancet. 2019 Jun 7. pii: S0140-6736(19)31271.
    PubMed     Abstract available


    May 2019
  51. LUO J, Gonsalves G, Greene J
    Insulin for all: treatment activism and the global diabetes crisis.
    Lancet. 2019;393:2116-2117.
    PubMed    


  52. RABER I, McCarthy CP, Vaduganathan M, Bhatt DL, et al
    The rise and fall of aspirin in the primary prevention of cardiovascular disease.
    Lancet. 2019;393:2155-2167.
    PubMed     Abstract available


  53. GREGG EW, Cheng Y, Imperatore G
    Trend analysis of diabetic mortality - Authors' reply.
    Lancet. 2019;393:1932.
    PubMed    


  54. YUAN X, Song F, Zhang L
    Trend analysis of diabetic mortality.
    Lancet. 2019;393:1931-1932.
    PubMed    


  55. WATTS G
    Shitaye Alemu Balcha: committed to rural health care in Ethiopia.
    Lancet. 2019;393:1797.
    PubMed    


    April 2019
  56. ZHONG D, Yi Y, Lin C
    A kidney changes size: first increasing and then decreasing.
    Lancet. 2019;393:1641.
    PubMed    


  57. TUTTLE KR
    A turning point for chronic kidney disease in diabetes.
    Lancet. 2019 Apr 12. pii: S0140-6736(19)30855.
    PubMed    


  58. HEERSPINK HJL, Parving HH, Andress DL, Bakris G, et al
    Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
    Lancet. 2019 Apr 12. pii: S0140-6736(19)30772.
    PubMed     Abstract available


    March 2019
  59. THE LANCET
    Gestational diabetes in England: cause for concern.
    Lancet. 2019;393:1262.
    PubMed    


  60. EVANS ML, Golubic R
    Technology to overcome clinical inertia in insulin therapy.
    Lancet. 2019;393:1078-1080.
    PubMed    


  61. COSTACOU T, Guo J, Miller RG, Orchard TJ, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:985.
    PubMed    


  62. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes - Authors' reply.
    Lancet. 2019;393:985-986.
    PubMed    


  63. SNAITH JR, Holmes-Walker DJ, Girgis CM, Greenfield JR, et al
    Excess mortality and cardiovascular disease risk in type 1 diabetes.
    Lancet. 2019;393:984-985.
    PubMed    


  64. XIAO F, Liu M, Wang XF
    Involuntary choreiform movements in a diabetic patient.
    Lancet. 2019;393:1033.
    PubMed    


    February 2019
  65. BERGENSTAL RM, Johnson M, Passi R, Bhargava A, et al
    Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial.
    Lancet. 2019 Feb 22. pii: S0140-6736(19)30368.
    PubMed     Abstract available


    January 2019
  66. STEDMAN M, Lunt M, Livingston M, Fryer AA, et al
    The costs of drug prescriptions for diabetes in the NHS.
    Lancet. 2019;393:226-227.
    PubMed    


  67. THE LANCET
    Modernising the NHS: leading the way with diabetes.
    Lancet. 2019;393:200.
    PubMed    


  68. VERMA S, Juni P, Mazer CD
    Pump, pipes, and filter: do SGLT2 inhibitors cover it all?
    Lancet. 2019;393:3-5.
    PubMed    


    December 2018
  69. SANYAL A, Charles ED, Neuschwander-Tetri BA, Loomba R, et al
    Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Lancet. 2018 Dec 13. pii: S0140-6736(18)31785.
    PubMed     Abstract available


  70. THE LANCET
    Type 2 diabetes: the urgent need to protect young people.
    Lancet. 2018;392:2325.
    PubMed    


    November 2018
  71. UNAMUNO X, Fruhbeck G
    Lorcaserin: balancing efficacy with potential risks.
    Lancet. 2018;392:2239-2240.
    PubMed    


  72. STUMVOLL M, Tschop M
    Twice the benefits with twincretins?
    Lancet. 2018;392:2142-2144.
    PubMed    


  73. ZELNIKER TA, Wiviott SD, Raz I, Im K, et al
    SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Lancet. 2018 Nov 9. pii: S0140-6736(18)32590.
    PubMed     Abstract available


    October 2018
  74. TAYLOR R, Adamson AJ, Sattar N, Lean MEJ, et al
    VLCD for weight loss and remission of type 2 diabetes? - Authors' reply.
    Lancet. 2018;392:1307.
    PubMed    


  75. AHMAD N, Alfaris N
    VLCD for weight loss and remission of type 2 diabetes?
    Lancet. 2018;392:1306-1307.
    PubMed    


  76. BOHULA EA, Scirica BM, Inzucchi SE, McGuire DK, et al
    Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.
    Lancet. 2018 Oct 3. pii: S0140-6736(18)32328.
    PubMed     Abstract available


  77. FRIAS JP, Nauck MA, Van J, Kutner ME, et al
    Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Lancet. 2018 Oct 3. pii: S0140-6736(18)32260.
    PubMed     Abstract available


  78. GALDERISI A, Sherr JL
    Enlarging the loop: closed-loop insulin delivery for type 1 diabetes.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32329.
    PubMed    


  79. TAUSCHMANN M, Thabit H, Bally L, Allen JM, et al
    Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)31947.
    PubMed     Abstract available


  80. HERNANDEZ AF, Green JB, Janmohamed S, D'Agostino RB Sr, et al
    Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32261.
    PubMed     Abstract available


  81. MAFHAM M, Preiss D
    HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?
    Lancet. 2018 Oct 1. pii: S0140-6736(18)32348.
    PubMed    


    September 2018

  82. NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4.
    Lancet. 2018;392:1072-1088.
    PubMed     Abstract available


    August 2018
  83. KLUGER AY, McCullough PA
    Semaglutide and GLP-1 analogues as weight-loss agents.
    Lancet. 2018;392:615-616.
    PubMed    


  84. RAWSHANI A, Sattar N, Franzen S, Rawshani A, et al
    Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.
    Lancet. 2018;392:477-486.
    PubMed     Abstract available


  85. BASINA M, Maahs DM
    Age at type 1 diabetes onset: a new risk factor and call for focused treatment.
    Lancet. 2018;392:453-454.
    PubMed    


  86. MCCALL C
    Biosimilars for insulin: a cost-saving alternative?
    Lancet. 2018;392:463-464.
    PubMed    


    July 2018
  87. PALMER SC, Strippoli GFM
    Metformin as first-line treatment for type 2 diabetes.
    Lancet. 2018;392:120.
    PubMed    


    June 2018
  88. RAYNER CK, Horowitz M
    Agonism of receptors in the gut-pancreas axis in type 2 diabetes: are two better than one?
    Lancet. 2018 Jun 22. pii: S0140-6736(18)30936.
    PubMed    


  89. AMBERY P, Parker VE, Stumvoll M, Posch MG, et al
    MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
    Lancet. 2018 Jun 22. pii: S0140-6736(18)30726.
    PubMed     Abstract available


  90. LANGENBERG C, Lotta LA
    Genomic insights into the causes of type 2 diabetes.
    Lancet. 2018;391:2463-2474.
    PubMed     Abstract available


  91. DIMEGLIO LA, Evans-Molina C, Oram RA
    Type 1 diabetes.
    Lancet. 2018;391:2449-2462.
    PubMed     Abstract available


  92. PATEL T, Tesfaldet B, Chowdhury I, Kettermann A, et al
    Endpoints in diabetes cardiovascular outcome trials.
    Lancet. 2018;391:2412.
    PubMed    


  93. STEYN M, Couchman L, Coombes G, Earle KA, et al
    A herbal treatment for type 2 diabetes adulterated with undisclosed drugs.
    Lancet. 2018;391:2411.
    PubMed    


  94. THE LANCET
    Untangling the complications of diabetes.
    Lancet. 2018;391:2389.
    PubMed    


    May 2018
  95. BENNETT PH
    Diabetes mortality in the USA: winning the battle but not the war?
    Lancet. 2018 May 18. pii: S0140-6736(18)30843.
    PubMed    


  96. GREGG EW, Cheng YJ, Srinivasan M, Lin J, et al
    Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data.
    Lancet. 2018 May 18. pii: S0140-6736(18)30314.
    PubMed     Abstract available


    March 2018
  97. CHATTERJEE S, Khunti K, Davies MJ
    Type 2 diabetes - Authors' reply.
    Lancet. 2018;391:1262.
    PubMed    


  98. TATE AR
    Type 2 diabetes.
    Lancet. 2018;391:1261-1262.
    PubMed    


  99. BOUSSAGEON R, Roustit M, Gueyffier F, Tudrej BV, et al
    Type 2 diabetes.
    Lancet. 2018;391:1261.
    PubMed    


    February 2018
  100. BHATT DL
    CABG the clear choice for patients with diabetes and multivessel disease.
    Lancet. 2018 Feb 22. pii: S0140-6736(18)30424.
    PubMed    


  101. SARHAN MB, Ghandour R, Rmeileh NMEA
    The effectiveness of counselling interventions in reducing HbA1c concentrations in patients with type 2 diabetes: a modelling study.
    Lancet. 2018;391 Suppl 2:S30.
    PubMed     Abstract available


  102. SAMAN KA, Massad S, Ibaid AA, Anan H, et al
    Factors associated with depression in patients with type 2 diabetes in the Gaza Strip: a cross sectional study.
    Lancet. 2018;391 Suppl 2:S19.
    PubMed     Abstract available


  103. CANALI G, Tittle V, Seita A
    Medication adherence by Palestine refugees living in Jordan who have diabetes: a cross-sectional study.
    Lancet. 2018;391 Suppl 2:S13.
    PubMed     Abstract available


  104. BERGENSTAL RM
    Continuous glucose monitoring: transforming diabetes management step by step.
    Lancet. 2018 Feb 15. pii: S0140-6736(18)30290.
    PubMed    


  105. HEINEMANN L, Freckmann G, Ehrmann D, Faber-Heinemann G, et al
    Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial.
    Lancet. 2018 Feb 15. pii: S0140-6736(18)30297.
    PubMed     Abstract available


    January 2018
  106. BARNETT R
    Type 1 diabetes.
    Lancet. 2018;391:195.
    PubMed    


    December 2017
  107. UUSITUPA M
    Remission of type 2 diabetes: mission not impossible.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33100.
    PubMed    


  108. LEAN ME, Leslie WS, Barnes AC, Brosnahan N, et al
    Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33102.
    PubMed     Abstract available


    November 2017
  109. BROWN DM, Wykoff CC
    Intravitreal aflibercept for proliferative diabetic retinopathy.
    Lancet. 2017;390:2141.
    PubMed    


  110. SIVAPRASAD S, Prevost AT, Vasconcelos J, Riddell A, et al
    Intravitreal aflibercept for proliferative diabetic retinopathy - Authors' reply.
    Lancet. 2017;390:2141-2142.
    PubMed    


  111. LIU L, Tham YC, Cheng CY
    Intravitreal aflibercept for proliferative diabetic retinopathy.
    Lancet. 2017;390:2140-2141.
    PubMed    


    October 2017
  112. MCGAVOCK J, Wicklow B, Dart AB
    Type 2 diabetes in youth is a disease of poverty.
    Lancet. 2017;390:1829.
    PubMed    


    September 2017
  113. GARG SK, Polsky S
    Continuous glucose monitoring in pregnant women with type 1 diabetes.
    Lancet. 2017 Sep 14. pii: S0140-6736(17)32449.
    PubMed    


  114. FEIG DS, Donovan LE, Corcoy R, Murphy KE, et al
    Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial.
    Lancet. 2017 Sep 14. pii: S0140-6736(17)32400.
    PubMed     Abstract available


  115. JEFFCOATE W, Barron E, Lomas J, Valabhji J, et al
    Using data to tackle the burden of amputation in diabetes.
    Lancet. 2017 Sep 11. pii: S0140-6736(17)32401.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: